April 27, 2020 / 12:06 PM / a month ago

BRIEF-Takeda Announces U.S. FDA Breakthrough Therapy Designation For Mobocertinib (TAK-788)

April 27 (Reuters) - Takeda Pharmaceutical Co Ltd:

* TAKEDA ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR MOBOCERTINIB (TAK-788) FOR THE TREATMENT OF NSCLC PATIENTS WITH EGFR EXON 20 INSERTION MUTATIONS

* TAKEDA PHARMACEUTICAL CO LTD - DESIGNATION REPRESENTS POSITIVE PROGRESS FOR A UNIQUE PATIENT POPULATION IN NEED OF TARGETED THERAPY OPTIONS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below